Renal Cell Carcinoma (Record no. 5252)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02278nam a22002537a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240305192341.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220219b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 4431555315 |
| International Standard Book Number | 9784431555315 |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | Data centre |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Mototsugu Oya |
| 9 (RLIN) | 31835 |
| 245 ## - TITLE STATEMENT | |
| Title | Renal Cell Carcinoma |
| Remainder of title | Molecular Features and Treatment Updates |
| 250 ## - EDITION STATEMENT | |
| Edition statement | illustrated |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Department of Urology Keio University School of Medicine Tokyo, Japan |
| Name of publisher, distributor, etc. | Springer |
| Date of publication, distribution, etc. | 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 381 pages |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Science / Life Sciences / Molecular Biology |
| 9 (RLIN) | 27008 |
| General subdivision | Medical / Research Medical / Urology |
| 9 (RLIN) | 31836 |
| General subdivision | Medical / Oncology / General |
| 9 (RLIN) | 26891 |
| General subdivision | Medical / Clinical Medicine |
| 9 (RLIN) | 26816 |
| General subdivision | Medical › Oncology › General |
| 9 (RLIN) | 26780 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Shelving location | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 02/19/2022 | EBS9727 | 02/19/2022 | 02/19/2022 | E-BOOKS |